A dose‐response study of HOE 498, a new non‐sulphydryl converting enzyme inhibitor, on blood pressure, pulse rate and the renin‐ angiotensin‐aldosterone system in normal man.

作者: PJ Manhem , SG Ball , JJ Morton , GD Murray , BJ Leckie

DOI: 10.1111/J.1365-2125.1985.TB02794.X

关键词: ChemistryAldosteroneInternal medicineAngiotensin IIEndocrinologyRenin–angiotensin systemBlood pressureAngiotensin-converting enzymeEnzyme inhibitorRamiprilPlasma renin activity

摘要: The effect of different oral doses HOE 498, a new non-sulphydryl containing converting enzyme inhibitor, was investigated in double-blind, placebo-controlled study normotensive volunteers. Dose-related reductions serum activity, plasma angiotensin II and aldosterone were seen, greater at 4 h than 12 after drug ingestion. Converse dose-related increases blood I active renin concentration occurred. Falls as great with 20 mg 50 although the more prolonged mg. concentrations activity correlated 498 - diacid plasma. falls both supine erect pressure maximal 2-3.5 dosing. Pulse rate increased marginally but insignificantly supine; slightly significantly upright position, concomitantly reduction all drug. We conclude that effects single on renin-angiotensin system are within h, still apparent 24 h. Thus it is likely once daily administration will be adequate for treatment high patients.

参考文章(31)
Ernest L. Wilkinson, Heikki Backman, Hans H. Hecht, Cardiovascular and renal adjustments to a hypotensive agent (l'hydrazinophthalazine: Ciba BA-5968: apresoline). Journal of Clinical Investigation. ,vol. 31, pp. 872- 879 ,(1952) , 10.1172/JCI102674
G P Hodsman, A M Cumming, Gordon Murray, J J Brown, J I Robertson, A F Lever, J J Morton, B W East, D L Davies, Enalapril (MK421) in the treatment of hypertension with renal artery stenosis Journal of Hypertension. ,vol. 1, pp. 109- ,(1983)
G P Hodsman, J J Brown, A M Cumming, D L Davies, B W East, A F Lever, J J Morton, G D Murray, I Robertson, J I Robertson, Enalapril in the treatment of hypertension with renal artery stenosis. BMJ. ,vol. 287, pp. 1413- 1417 ,(1983) , 10.1136/BMJ.287.6403.1413
GP Hodsman, JR Zabludowski, C Zoccali, R Fraser, JJ Morton, GD Murray, JI Robertson, Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man. British Journal of Clinical Pharmacology. ,vol. 17, pp. 233- 241 ,(1984) , 10.1111/J.1365-2125.1984.TB02337.X
A P Niarchos, T G Pickering, D B Case, P Sullivan, J H Laragh, Role of the renin-angiotensin system in blood pressure regulation. The cardiovascular effects of converting enzyme inhibition in normotensive subjects. Circulation Research. ,vol. 45, pp. 829- 837 ,(1979) , 10.1161/01.RES.45.6.829
A.B Atkinson, J.I.S Robertson, CAPTOPRIL IN THE TREATMENT OF CLINICAL HYPERTENSION AND CARDIAC FAILURE The Lancet. ,vol. 314, pp. 836- 839 ,(1979) , 10.1016/S0140-6736(79)92186-X
D.B. Brunner, G. Desponds, J. Biollaz, I. Keller, F. Ferber, H. Gavras, H.R. Brunner, J.L. Schelling, Effect of a new angiotensin converting enzyme inhibitor MK 421 and its lysine analogue on the components of the renin system in healthy subjects British Journal of Clinical Pharmacology. ,vol. 58, pp. S778- S784 ,(2004) , 10.1111/J.1365-2125.2004.02294.X
G. A. MacGregor, N. D. Markandu, J. E. Roulston, J. C. Jones, J. J. Morton, Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature. ,vol. 291, pp. 329- 331 ,(1981) , 10.1038/291329A0
P. U. Witte, R. Irmisch, P. Hajd�, H. Metzger, Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects European Journal of Clinical Pharmacology. ,vol. 27, pp. 577- 581 ,(1984) , 10.1007/BF00556895
Jack Lieberman, Elevation of serum angiotension-converting-enzyme (ACE) level in sarcoidosis The American Journal of Medicine. ,vol. 59, pp. 365- 372 ,(1975) , 10.1016/0002-9343(75)90395-2